ProShares Trust ProShares Metaverse ETF (ARCA: VERS)

Últimas noticias sobre ProShares Trust ProShares Metaverse ETF (ARCA:VERS)

Technology

Communication Services

Consumer Cyclical

Other

Real Estate

Healthcare

The Fund invests in financial instruments that ProShare Advisors believes, in combination, should track the performance of the Index. The Index is designed to measure the performance of companies that provide or use innovative technologies to offer products and services around the metaverse. Metaverse is a term used to refer to a digital world or a future iteration of the internet. The Metaverse is characterized by virtual worlds that create a simulated environment as well as augmented reality where the real-world environment is enhanced by computer generated sensory information. Metaverse is expected to allow people to engage in new ways, such as through internet-based interactions, online gaming and transactions. Metaverse is enabled by several connected technologies, such as virtual and augmented reality, digital environments, artificial intelligence and advanced computing.

Roblox Corp -Class A

Fubotv Inc

Apple Inc

Immersion Corp Com

Amazon.Com Inc

NVIDIA Corporation

Alphabet Inc-cl A

Exp World Holdings, Inc.

Microsoft Corp

Meta Platforms Inc

Himax Technologies Inc -sp Adr

Qualcomm Inc

Microvision Inc

Take-Two Interactive Softwre

ProShares Metaverse ETF

Equities

News

Small Cap

Tech

FUBO

VERS

Las acciones de fuboTV caen tras la disputa con TelevisaUnivision, que retira su programación. Fubo critica prácticas injustas.

Acciones de fuboTV (FUBO) caen tras retirada de programación de TelevisaUnivision

ProShares Trust ProShares Metaverse ETF

VERSES AI Inc

VERSES AI Inc Class A (Sub Voting)

VersaBank

VERSACOM INTL INC by VersaCOM International, Inc.

Versacom International Inc

VERSAILLES FINANCIAL CORP by Versailles Financial Corp.

Versailles Financial Corp

Versant PWR

Versarien PLC

Verso

Versus Systems Inc

D. Boral Capital analyst Jason Kolbert maintains Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and maintains $15 price target.

Price Target

Analyst Ratings

CRMD

D. Boral Capital Maintains Buy on Cormedix, Maintains $15 Price Target

WIIM

Bioventus shares are trading lower following Q1 reported financial results.

CorMedix shares are trading higher after the company reported better-than-expected Q1 financial results.

JBDI

JBDI Holdings shares are trading higher after the company announced a $1.0 million share repurchase program.

WLFC

Willis Lease Finance shares are trading lower after the company reported worse-than-expected Q1 EPS results.

PACK

Ranpak Holdings shares are trading lower after the company reported Q1 financial results and missed its EPS estimate.

TRUE

TrueCar shares are trading lower. The company reported Q1 financial results.

Boise Cascade shares are trading lower after the company reported worse-than-expected Q1 EPS results.

Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) shares were trading higher in the premarket session on Tuesday after <a href="https://www.benzinga.com/pressreleases/25/05/b45217005/adm-reports-first-quarter-2025-results-affirms-full-year-eps-guidance" target="_blank" rel="noopener">the company reported</a><a href="https://www.benzinga.com/pressreleases/25/05/b45217005/adm-reports-first-quarter-2025-results-affirms-full-year-eps-guidance" target="_blank" rel="noreferrer noopener"> first-quarter results.</a>
The company reported quarterly adjusted earnings per share of 70 cents, beating the Street view of 67 cents. Quarterly sales of $20.18 billion missed the analyst consensus estimate of $21.94 billion.
Earnings before income taxes were $353 million for the first quarter ended March 31, down 60% from the prior-year quarter.
The total segment operating profit was $747 million, down 38% from the prior year&#8217;s quarter. It excluded $49 million in specified items, primarily driven by restructuring charges.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45214905/marriott-international-advanced-micro-devices-and-3-stocks-to-watch-heading-into-tuesday" rel="noreferrer noopener">Marriott International, Advanced Micro Devices And 3 Stocks To Watch Heading Into Tuesday</a>
The Ag Services and Oilseeds segment operating profit was $412 million, down 52% year over year. The Carbohydrate Solutions segment operating profit was $240 million, down 3%. The Nutrition segment operating profit was $95 million, up 13%.
The company reported a trailing four-quarter average return on invested capital (ROIC) of 5.4% and an adjusted ROIC of 7.0% over the same period.
&#8220;Looking forward, the focused execution of our team will be foundational to navigating market uncertainty,&#8221; said Juan Luciano, CEO and board chair.
Outlook: &#8220;Based on our self-help agenda and execution agility, we are reaffirming our full-year guidance for 2025 but expect to deliver at the lower end of the range, given current market conditions,&#8221; Luciano added.
Archer-Daniels-Midland reaffirmed its full-year 2025 adjusted EPS guidance of $4.00 to $4.75, compared to the Street estimate of $4.10.
The firm <a target="_blank" href="https://s1.q4cdn.com/365366812/files/doc_financials/2025/q1/ADM-2025-03-31-CallDeck-2.pdf" rel="noreferrer noopener">noted </a>signs of weakening customer demand, particularly in its Carbohydrate Solutions segment, and has lowered volume expectations for select markets and products.
Price Action: At last check on Tuesday, ADM shares were trading higher by 0.53% to $47.75 premarket.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/25/05/45215302/a-breakout-is-near-as-gold-surges-above-3380-and-silver-starts-to-perk-up-says-peter-schiff" target="_blank" rel="noreferrer noopener">Bitcoin Critic Peter Schiff Says A &#8216;Breakout Is Near&#8217; As Gold Surges Above $3,380, Silver Starts To Perk Up</a></li>
</ul>
Photo: Shutterstock

Earnings

Guidance

Markets

Movers

General

What's Going On With Archer-Daniels-Midland Stock Today?

INSP

Inspire Medical Systems shares are trading lower after Morgan Stanley, JP Morgan, and Wells Fargo cut their respective price targets on the stock.

JJSF

J&J Snack Foods shares are trading lower after the company reported worse-than-expected Q2 financial results.

Air Lease shares are trading higher after the company reported better-than-expected Q1 financial results.

Valaris shares are trading higher after the company announced it secured a $135 million contract for its drillship VALARIS DS-15 and agreed to sell the jackup VALARIS 247 to BW Energy for $108 million. Barclays raised its price target on the stock from $35 to $37.

Barclays analyst Julian Mitchell maintains Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) with a Overweight and lowers the price target from $85 to $84.

Barclays Maintains Overweight on Fortive, Lowers Price Target to $84

Barclays analyst Matthew Murphy maintains First Quantum Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FM#TSX">FM</a>) with a Overweight and raises the price target from C$21.4 to C$21.6.

TSX:FM

Barclays Maintains Overweight on First Quantum Minerals, Raises Price Target to C$21.6

Animal health firm Zoetis Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) on Tuesday reported a first-quarter 2025 adjusted EPS of $1.48, up from $1.38 a year ago, beating the <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">consensus of $1.39</a>.
Adjusted net income for the first quarter of 2025 was $662 million, or $1.48 per diluted share. That&#8217;s an increase of 6% and 8%, respectively, <a href="https://www.benzinga.com/pressreleases/25/05/b45217035/zoetis-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">on an organic operational basis</a>.
Adjusted net income for the first quarter of 2025 excludes the net impact of $31 million for purchase accounting adjustments, acquisition and divestiture-related costs, and certain significant items.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45208077/elanco-animal-health-sells-xdemvy-royalties-to-blackstone-in-295-million-deal-to-lower-debt" rel="noreferrer noopener">Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal</a>
The company reported sales of $2.22 billion, up 1% year over year, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $2.19 billion</a>.
On an organic operational&nbsp;basis, revenue for the first quarter of 2025 increased 9% compared with the first quarter of 2024.
Revenue in the U.S. segment was $1.2 billion, an increase of 2% compared with the first quarter of 2024 and an increase of 6% on an organic operational basis.
Sales of companion animal products increased by 8%, driven by Simparica Trio, the company&#8217;s flea tick and heartworm combination product, key dermatology products Apoquel&nbsp;and Cytopoint, and monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela&nbsp;for dogs and Solensia&nbsp;for cats.
Guidance: Zoetis raised its fiscal 2025 revenues guidance from $9.225 billion &#8211; $9.375 billion to  $9.425 billion &#8211; $9.575 billion, compared to the consensus of $9.33 billion.
The company maintains an organic operational growth of 6% to 8%. It expects a reported net income of $2.630 billion—$2.68 billion, compared to <a href="https://www.benzinga.com/general/health-care/25/02/43697905/zoetis-drops-as-2025-guidance-falls-short-of-estimates" target="_blank" rel="noreferrer noopener">prior guidance of $2.57 billion &#8211; $2.62 billion</a>.
The animal company raised its adjusted net income guidance to $2.775 billion &#8211; $2.825 billion from $2.70 billion and $2.75 billion, with organic operational growth of 6% to 8% (compared to 5% &#8211; 7% earlier).
Zoetis forecasts a reported EPS of $5.85 to $5.95 compared to prior guidance of $5.70-$5.80 and adjusted EPS of $6.20-$6.30 from between $6.00 and $6.10, compared to a consensus of $6.09.
The company says the guidance reflects foreign exchange rates as of late April and the impact of enacted tariffs.
Price Action:&nbsp;ZTS stock is down 1.11% at $156.30 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45209967/biocryst-pharmaceuticals-soars-23-in-one-session-heres-why-it-surprised-investors" target="_blank" rel="noreferrer noopener">BioCryst Pharmaceuticals Soars 23% In One Session &#8211; Here&#8217;s Why It Surprised Investors</a></li>
</ul>

Large Cap

Health Care

Zoetis Beats Wall Street Estimates, Revises 2025 Guidance To Include Tariffs Impact

BIAF

BioAffinity Technologies shares are trading lower after the company announced the pricing of its $3.25 million offering.

Barclays analyst George Wang maintains Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) with a Equal-Weight and lowers the price target from $245 to $234.

Barclays Maintains Equal-Weight on Fabrinet, Lowers Price Target to $234

ThredUp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) reported a good first-quarter beat and raised its <a href="https://www.benzinga.com/quote/TDUP/guidance">full-year guidance</a>, driven by record new buyer growth, according to Telsey Advisory Group.
The ThredUp Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5888c53977f9dd0001877a22/dana-telsey">Analyst Dana Telsey</a> maintained an Outperform rating, while raising the price target from $6 to $7.
The ThredUp Thesis: The company reported better-than-expected results "across the board," with total revenue of $71.3 million and adjusted EBITDA of $3.8 million, topping consensus of $2.2 million and $68.2 million, respectively, Telsey said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
ThredUp posted a record 95% growth in new buyers in the first quarter, "while orders also grew mid-teens in the period," the analyst added.
Strong new buyer growth continued into the second quarter, with April recording the strongest customer acquisition month in the company&#8217;s history, Telsey stated.
Management raised their 2025 revenue guidance from $270-$280 million to $281-$291 million, ahead of consensus of $276.4 million, Telsey said. The new revenue guidance reflects "an improvement in the remainder of the year," she further wrote.
TDUP Price Action: Shares of ThredUp jumped 32% to $5.88 at the time of publication on Tuesday.
Read More: 
<ul>
<li><a href="https://in.benzinga.com/content/44890152/j-b-hunt-transport-overcorrects-into-a-buying-opportunity"> Top 2 Consumer Stocks That May Implode In May</a>  </li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings Beats

Long Ideas

Reiteration

Trading Ideas

TDUP

ThredUp Shares Jump 32% On Record Customer Growth, Upbeat Forecast; Analyst Sees More Upside

OTTR

Otter Tail shares are trading lower after the company reported worse-than-expected Q1 sales results and issued FY25 EPS guidance below estimates.

Comments

ProShares Trust ProShares Metaverse ETF

Noticias

Últimas noticias sobre ProShares Trust ProShares Metaverse ETF (ARCA:VERS)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL